[8-K] AN2 Therapeutics, Inc. Reports Material Event

Rhea-AI Filing Summary

AN2 Therapeutics reported that it issued a press release announcing its financial results for the second quarter ended June 30, 2025. The press release is furnished as Exhibit 99.1 and is incorporated by reference into this Form 8-K. The filing states that the information in Item 2.02 and Item 9.01 (including Exhibit 99.1) is furnished and shall not be deemed "filed" under Section 18 of the Exchange Act, and will not be incorporated by reference in other filings except by specific reference. The report is dated August 12, 2025 and is signed by Chief Executive Officer Eric Easom.

Positive

• Press release furnished announcing second-quarter 2025 results and attached as Exhibit 99.1
• Form 8-K signed by CEO Eric Easom, indicating authorized disclosure

Negative

• None.

Insights

Financial Analyst

TL;DR: Routine earnings disclosure via furnished press release; financial detail resides in Exhibit 99.1, not the 8-K text itself.

The Form 8-K notifies investors that AN2 Therapeutics has publicly released its second-quarter 2025 financial results through a press release attached as Exhibit 99.1. The filing makes clear the press release is "furnished" and not "filed," which limits its incorporation into other SEC filings unless expressly referenced. Because the 8-K does not include numerical results or tables, material financial analysis must come from the attached press release rather than the 8-K cover notice.

Corporate Governance Expert

TL;DR: Formal, timely disclosure; legal designation of the exhibit as furnished affects incorporation rights.

The company followed standard disclosure practice by furnishing a press release as Exhibit 99.1 and signing the Form 8-K through its CEO, indicating authorized release. The filing explicitly states the exhibit is furnished and not filed for Section 18 purposes, which is a meaningful legal distinction for how the content may be relied upon in future filings.

false000188043800018804382025-08-122025-08-12

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 12, 2025

AN2 Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-41331	82-0606654
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
1800 El Camino Real, Suite D
Menlo Park, California				94027
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 650 331-9090

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		ANTX		The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 12, 2025, AN2 Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2025. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

All of the information furnished in this Item 2.02 and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

Exhibit Number		Description
99.1		Press Release of AN2 Therapeutics Inc. dated August 12, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			AN2 Therapeutics, Inc.
Date:	August 12, 2025	By:	/s/ Eric Easom
			Eric Easom Chief Executive Officer and Director (Principal Executive Officer)

FAQ

What did AN2 Therapeutics (ANTX) report in this 8-K?

AN2 furnished a press release announcing its financial results for the quarter ended June 30, 2025, attached as Exhibit 99.1.

Is the press release in the 8-K considered "filed" with the SEC?

No. The filing states the information (including Exhibit 99.1) is "furnished" and shall not be deemed "filed" under Section 18 of the Exchange Act.

Does the 8-K include the company’s financial statements or numeric results?

No numeric financial data are included in the Form 8-K text; the financial results are contained in the attached press release (Exhibit 99.1).

When was this Form 8-K filed and who signed it?

The report is dated August 12, 2025 and is signed by Eric Easom, Chief Executive Officer and Director.

Where can I find the full financial details for Q2 2025?

Review Exhibit 99.1 (the press release furnished with this Form 8-K) for the complete financial results and disclosures.